AUROBINDO PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,265 INR | +1.11% |
|
+5.39% | +16.71% |
| 06-05 | Hindalco-owned Novelis delays US IPO; shares slide | RE |
| 05-27 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 8.78B | ||||||
| 754B | ||||||
| 630B | ||||||
| 352B | ||||||
| 331B | ||||||
| 298B |
